Research programme: antiviral therapeutics - Galapagos

Drug Profile

Research programme: antiviral therapeutics - Galapagos

Latest Information Update: 03 Mar 2015

Price : $50

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; Rega Institute for Medical Research; University Hospital Heidelberg
  • Class
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Hepatitis B

Most Recent Events

  • 12 Feb 2015 Early research in Hepatitis B in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top